Nationally authorised medicinal products
![EU flag](/CropUp/factbox/cu-48A91973F3574E40ADED37EF2B6C3D3A-en-1.jpg)
We advise holders of marketing authorisations for purely nationally authorised medicines that even though they are nationally authorised medicines, it may be necessary to make changes as a result of Brexit before the cut-off date.
As with MRP/DCP authorised medicines, it is important to determine if it is necessary to change, for example, the marketing authorisation holder, batch control as well as the batch-release site, etc. because the UK will generally be considered a third country after the cut-off date.
For more information about this, please see the Q&As published by the coordination groups for human and veterinary medicinal products in the EU (CMDh/v).
We encourage everyone to implement any needed changes well before the cut-off date.
Changes and questions to nationally authorised products (NAPs) can be sent to Send an email
Links
CMDh Brexit information including Q&A
CMDv Brexit information including Q&A